-+ 0.00%
-+ 0.00%
-+ 0.00%

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Benzinga·11/05/2024 12:05:41
Listen to the news

Gainers

  • Bionomics (NASDAQ:BNOX) shares moved upwards by 115.4% to $0.41 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.4 million.
  • Cocrystal Pharma (NASDAQ:COCP) shares increased by 12.37% to $2.09. The company's market cap stands at $21.2 million.
  • QT Imaging Holdings (NASDAQ:QTI) stock moved upwards by 12.09% to $0.66. The market value of their outstanding shares is at $14.1 million.
  • Cyclerion Therapeutics (NASDAQ:CYCN) stock increased by 10.38% to $2.91. The market value of their outstanding shares is at $7.3 million.
  • Bluejay Diagnostics (NASDAQ:BJDX) shares increased by 9.73% to $0.08. The company's market cap stands at $1.3 million.
  • Hims & Hers Health (NYSE:HIMS) stock moved upwards by 8.86% to $22.6. The company's market cap stands at $4.8 billion. The company's, Q3 earnings came out yesterday.

Losers

  • Verrica Pharmaceuticals (NASDAQ:VRCA) stock declined by 32.2% to $0.97 during Tuesday's pre-market session. The company's market cap stands at $41.3 million. As per the press release, Q3 earnings came out yesterday.
  • Tactile Systems Tech (NASDAQ:TCMD) shares declined by 14.43% to $12.93. The company's market cap stands at $309.8 million. The company's, Q3 earnings came out yesterday.
  • Apellis Pharmaceuticals (NASDAQ:APLS) stock declined by 11.77% to $25.2. The market value of their outstanding shares is at $3.0 billion. As per the press release, Q3 earnings came out today.
  • Theriva Biologics (AMEX:TOVX) shares fell 10.63% to $1.85. The company's market cap stands at $2.5 million.
  • Lixte Biotechnology (NASDAQ:LIXT) shares decreased by 10.26% to $1.75. The market value of their outstanding shares is at $3.9 million.
  • Silexion Therapeutics (NASDAQ:SLXN) shares declined by 8.51% to $0.23. The company's market cap stands at $3.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.